PMID- 27825337
OWN - NLM
STAT- MEDLINE
DCOM- 20170116
LR  - 20240326
IS  - 1472-6882 (Electronic)
IS  - 1472-6882 (Linking)
VI  - 16
IP  - 1
DP  - 2016 Nov 9
TI  - Reno-protective effect and mechanism study of Huang Lian Jie Du Decoction on 
      lupus nephritis MRL/lpr mice.
PG  - 448
LID - 448
AB  - BACKGROUND: Huang Lian Jie Du Decoction (HLJDD), a very famous traditional 
      Chinese medicinal prescription, has been used for heat dissipation and 
      detoxification in China. This study was aimed to evaluate the reno-protective 
      effects of HLJDD against lupus nephritis (LN) in vivo in MRL/lpr mice. METHODS: 
      Animals were administered orally every day for eight consecutive weeks except the 
      mice of normal group and model group. Organ indexes, serum interleukin-6 (IL-6), 
      interleukin-10 (IL-10), interferon-gamma (IFN-gamma) and the anti-double stranded DNA 
      (anti-dsDNA) antibody were tested, respectively. Creatinine (Cr), blood urea 
      nitrogen (BUN) and urine protein were measured for renal function evaluation. The 
      expression of phosphorylated signal transducer and activator of transcription 3 
      (p-STAT 3) in kidney tissue was observed by western blot (WB) and 
      immunohistochemical (IHC) method. Meanwhile, histopathological changes in the 
      renal were studied by hematoxylin-eosin (H&E) staining. RESULTS: The mice of 
      HLJDD-treated group exhibited a significant reduced mortality (p < 0.05), serum 
      anti-dsDNA level (p < 0.05) and renal immune complex deposition (p < 0.05), 
      compared with the untreated MRL/lpr mice. In addition, HLJDD treatment remarkably 
      reduced the levels of BUN, Cr, proteinuria (p < 0.01) and the levels of 
      inflammatory cytokines such as IL-6, IL-10 and IFN-gamma (p < 0.01). Moreover, HLJDD 
      significantly suppressed the phosphorylations of STAT 3 (p < 0.05) and the renal 
      pathological changes. CONCLUSIONS: The study implied that HLJDD may be a 
      potential agent for the therapy of LN, and the down-regulated p-STAT 3 expression 
      suggesting that it may be one of the LN therapy targets for HLJDD.
FAU - Nie, Xiaoli
AU  - Nie X
AD  - School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 
      510515, People's Republic of China. nxl117@163.com.
AD  - Department of Traditional Chinese Medicine, Nanfang Hospital, Southern Medical 
      University, Guangzhou, 510515, People's Republic of China. nxl117@163.com.
FAU - Deng, Rong
AU  - Deng R
AD  - School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 
      510515, People's Republic of China.
FAU - Xiang, Lei
AU  - Xiang L
AD  - School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 
      510515, People's Republic of China.
FAU - Jiang, Pingping
AU  - Jiang P
AD  - School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 
      510515, People's Republic of China.
FAU - Xue, Qi
AU  - Xue Q
AD  - Department of General Surgery, Nanfang Hospital, Southern Medical University, 
      Guangzhou, 510515, People's Republic of China. xueqi_gz@163.com.
LA  - eng
PT  - Journal Article
DEP - 20161109
PL  - England
TA  - BMC Complement Altern Med
JT  - BMC complementary and alternative medicine
JID - 101088661
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Interleukin-6)
RN  - 130068-27-8 (Interleukin-10)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Animals
MH  - Disease Models, Animal
MH  - Drugs, Chinese Herbal/*administration & dosage
MH  - Female
MH  - Humans
MH  - Interferon-gamma
MH  - Interleukin-10/genetics/immunology
MH  - Interleukin-6/genetics/immunology
MH  - Kidney
MH  - Lupus Nephritis/*drug therapy/genetics/immunology
MH  - Mice
MH  - Mice, Inbred MRL lpr
MH  - Signal Transduction
PMC - PMC5101683
OTO - NOTNLM
OT  - Huang Lian Jie Du Decoction
OT  - Immune function
OT  - Lupus nephritis
OT  - MRL/lpr mice
OT  - p-STAT 3
EDAT- 2016/11/09 06:00
MHDA- 2017/01/17 06:00
PMCR- 2016/11/09
CRDT- 2016/11/10 06:00
PHST- 2016/06/21 00:00 [received]
PHST- 2016/11/02 00:00 [accepted]
PHST- 2016/11/10 06:00 [entrez]
PHST- 2016/11/09 06:00 [pubmed]
PHST- 2017/01/17 06:00 [medline]
PHST- 2016/11/09 00:00 [pmc-release]
AID - 10.1186/s12906-016-1433-1 [pii]
AID - 1433 [pii]
AID - 10.1186/s12906-016-1433-1 [doi]
PST - epublish
SO  - BMC Complement Altern Med. 2016 Nov 9;16(1):448. doi: 10.1186/s12906-016-1433-1.